CD44-Targeted nanoparticles for remodeling the tumor microenvironment in a 3D Macrophage-Embedded ovarian cancer model with stem Cell-Like features DOI

Samjhana Shrestha,

Anil K Giri,

Prabhat Shrestha

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125483 - 125483

Published: March 1, 2025

Language: Английский

Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge DOI Creative Commons
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang

et al.

Journal of Molecular Biology, Journal Year: 2025, Volume and Issue: unknown, P. 169050 - 169050

Published: Feb. 1, 2025

Language: Английский

Citations

0
Farnesyl Transferase Inhibitors as a Novel Strategy for Targeting KRAS-Dependent Cancers DOI Creative Commons
Robert B. Kargbo

ACS Medicinal Chemistry Letters, Journal Year: 2025, Volume and Issue: 16(4), P. 517 - 519

Published: March 11, 2025

KRAS mutations drive tumorigenesis in multiple cancers, yet direct inhibitors display limited efficacy due to adaptive resistance. Recent preclinical findings indicate farnesyl transferase (FTIs) can reduce compensatory mTOR and MAPK pathway activation. Evidence supports combining FTIs with enhance tumor suppression delayed

Language: Английский

Citations

0
CD44-Targeted nanoparticles for remodeling the tumor microenvironment in a 3D Macrophage-Embedded ovarian cancer model with stem Cell-Like features DOI

Samjhana Shrestha,

Anil K Giri,

Prabhat Shrestha

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125483 - 125483

Published: March 1, 2025

Language: Английский

Citations

0